BioAge Labs (BIOA) Competitors $4.42 -0.10 (-2.21%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock BIOA vs. AUTL, KALV, AVBP, DNTH, VIR, ANAB, TSHA, ORGO, TBPH, and MAZEShould you be buying BioAge Labs stock or one of its competitors? The main competitors of BioAge Labs include Autolus Therapeutics (AUTL), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Dianthus Therapeutics (DNTH), Vir Biotechnology (VIR), AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Theravance Biopharma (TBPH), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry. BioAge Labs vs. Its Competitors Autolus Therapeutics KalVista Pharmaceuticals ArriVent BioPharma Dianthus Therapeutics Vir Biotechnology AnaptysBio Taysha Gene Therapies Organogenesis Theravance Biopharma Maze Therapeutics Autolus Therapeutics (NASDAQ:AUTL) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership. Does the media favor AUTL or BIOA? In the previous week, Autolus Therapeutics had 19 more articles in the media than BioAge Labs. MarketBeat recorded 24 mentions for Autolus Therapeutics and 5 mentions for BioAge Labs. Autolus Therapeutics' average media sentiment score of 0.79 beat BioAge Labs' score of -0.11 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, AUTL or BIOA? BioAge Labs has lower revenue, but higher earnings than Autolus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.12M47.07-$220.66M-$0.84-2.13BioAge LabsN/AN/A-$71.11MN/AN/A Do institutionals & insiders believe in AUTL or BIOA? 72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 20.8% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is AUTL or BIOA more profitable? BioAge Labs' return on equity of -25.39% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -56.18% -29.61% BioAge Labs N/A -25.39%-23.22% Do analysts rate AUTL or BIOA? Autolus Therapeutics presently has a consensus target price of $9.12, indicating a potential upside of 409.50%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Autolus Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAutolus Therapeutics beats BioAge Labs on 8 of the 11 factors compared between the two stocks. Get BioAge Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetricBioAge LabsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$162.04M$806.48M$2.55B$9.80BDividend YieldN/A4.84%2.55%4.08%P/E RatioN/A1.1522.0525.12Price / SalesN/A25.5885.77109.31Price / CashN/A19.5623.4559.16Price / Book0.546.5830.926.24Net Income-$71.11M-$4.93M$31.01M$265.56M7 Day Performance-1.34%-0.17%0.10%0.90%1 Month Performance-4.54%-0.30%0.91%1.88%1 Year PerformanceN/A20.91%28.21%20.09% BioAge Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOABioAge LabsN/A$4.42-2.2%N/AN/A$162.04MN/A0.00N/AAUTLAutolus Therapeutics3.0131 of 5 stars$2.33-0.9%$9.32+300.0%-49.9%$620.11M$9.01M-2.65330Earnings ReportAnalyst UpgradeGap UpKALVKalVista Pharmaceuticals3.9888 of 5 stars$12.41-2.0%$26.29+111.8%+11.2%$619.93MN/A-3.36100AVBPArriVent BioPharma2.4093 of 5 stars$17.99-3.0%$39.29+118.4%-21.0%$615.49MN/A-4.7740DNTHDianthus Therapeutics1.3542 of 5 stars$18.76-2.0%$53.00+182.5%-27.1%$603.32M$6.52M-5.7780VIRVir Biotechnology3.3243 of 5 stars$4.30-1.1%$30.25+603.5%-48.0%$597.34M$74.21M-1.08580Positive NewsANABAnaptysBio2.9551 of 5 stars$21.03+3.2%$47.75+127.1%-41.1%$588.78M$111.87M-4.69100High Trading VolumeTSHATaysha Gene Therapies3.4714 of 5 stars$2.72-3.2%$8.17+200.2%+30.2%$583.88M$7.22M-8.00180Earnings ReportAnalyst RevisionORGOOrganogenesis4.2635 of 5 stars$4.55+0.7%$7.50+64.8%+78.9%$577.82M$458.76M-32.50950TBPHTheravance Biopharma2.1764 of 5 stars$11.52+2.8%$21.33+85.2%+67.2%$576.01M$65.27M-9.76110Analyst UpgradeHigh Trading VolumeMAZEMaze TherapeuticsN/A$13.14-1.4%$25.60+94.8%N/A$575.49M$167.50M0.00121Positive NewsEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies AUTL Alternatives KALV Alternatives AVBP Alternatives DNTH Alternatives VIR Alternatives ANAB Alternatives TSHA Alternatives ORGO Alternatives TBPH Alternatives MAZE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAge Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAge Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access